Recipient: Dr Andrew Moore
Institute: University of Queensland Diamantina Institute
Funding: $474,591 July 2014 to June 2019
Acute myeloid leukaemia (AML) is an aggressive leukaemia with a very poor prognosis for relapsed patients.
This project focusses on the most common subtype of AML, which sadly has a low survival rate due to high-risk of relapse in patients who initially appear to be in remission following therapy, but actually have very low levels of persistent leukaemia.

This research will develop new ways of monitoring the response to therapy, detect impending relapse, and identify specific markers associated with relapse in AML patients.

The insights gained from this research will inform future studies aimed at developing new therapies to prevent relapse and to treat patients who are not cured by currently available treatments.
Science is the solution for kids with cancer
The only way to improve outcomes for children diagnosed with cancer is through advances in medical research. Every day and every donation takes us closer to a cure.
Select your donation details
Please enter the amount you would like to donate

The Kids' Cancer Project is an ACNC Registered Charity 
ABN 13 061 138 181 | CFN 10581